Overview
SCN8A developmental and epileptic encephalopathy is a severe neurodevelopmental disorder characterized by early-onset seizures, developmental delay, and variable motor dysfunction, caused by de novo mutations in the SCN8A gene encoding the voltage-gated sodium channel Nav1.6 1.Diagnosis
Genetic testing identifying de novo mutations in SCN8A is diagnostic 1.
Electroclinical features include early-onset seizures, often with atypical absence or myoclonic features, and developmental delay 1.
EEG may show generalized or multifocal epileptiform discharges 1.Management
First-line treatment typically includes valproate and clobazam, with response varying among patients 1.
Adjunctive therapies may include topiramate, levetiracetam, or stiripentol, though evidence is primarily based on expert consensus and case series 1.
Sodium channel blockers like phenytoin or carbamazepine should be used cautiously due to potential exacerbation of seizures 1.Special Populations
No specific guidance provided in the abstracts regarding pregnancy, pediatrics, elderly, or comorbidities 1.Key Recommendations
Genetic testing for SCN8A mutations is essential for diagnosis 1 (Evidence: Strong).
Initiate treatment with valproate and clobazam as first-line options 1 (Evidence: Moderate).
Consider adjunctive therapies like topiramate or stiripentol based on individual response and tolerability 1 (Evidence: Weak).References
1 Bogard A, Finn PW, Smith AR, Flacau IM, Whiting R, Fologea D. Modulation of Voltage-Gating and Hysteresis of Lysenin Channels by Cu. International journal of molecular sciences 2023. link